Prostate Cell News Volume 9.31 | Aug 17 2018

TOP STORY

Identification of an Oncogenic Network with Prognostic and Therapeutic Value in Prostate Cancer

Researchers performed a meta-analysis of human prostate samples using weighted gene co-expression network analysis combined with experimental androgen receptor (AR) variant transcriptome analyses. An AR variant-driven gene module that is upregulated during human prostate cancer progression was identified. [Mol Syst Biol] Full Article

(Ranked by impact factor of the journal)

A Novel Cross-Talk between CXCR4 and PI4KIIIα in Prostate Cancer Cells

CXCR4 interacted with phosphatidylinositol 4-kinase IIIα (PI4KIIIα) membrane targeting machinery recruiting them to the plasma membrane for PI4P production. Consistent with this interaction, PI4KIIIα was found tightly linked to the CXCR4 induced prostate cancer cell invasion. [Oncogene] Abstract

The miR-96 and RARγ Signaling Axis Governs Androgen Signaling and Prostate Cancer Progression

Reflecting a significant genomic role for RARγ to regulate androgen signaling, RARγ knockdown in HPr1-AR cells significantly regulated the magnitude of the androgen receptor transcriptome. RARγ downregulation was explained by increased miR-96 in prostate cancer (PCa) cell and mouse models, and TCGA PCa cohorts. Biochemical approaches confirmed that miR-96 directly regulated RARγ expression and function. [Oncogene] Full Article

Mechanistic Insights of Epithelial Protein Lost in Neoplasm in Prostate Cancer Metastasis

EPLINα overexpression reduced cell growth, migration and invasion, and influenced transcript, protein and phosphoprotein expression of paxillin, FAK and Src. EPLIN knockdown increased the invasive and migratory nature of CA-HPV-10 cells and also induced changes to FAK and Src total and/or phospho expression. [Int J Cancer] Abstract

Inhibiting Geranylgeranyl Diphosphate Synthesis Reduces Nuclear Androgen Receptor Signaling and Neuroendocrine Differentiation in Prostate Cancer Cell Models

Under treatment with digeranyl bisphosphonate, nuclear localization of androgen receptor (AR) decreased in LNCaP, 22Rv1, and C4-2B4 cell lines, luciferase reporter activity was reduced in LNCaP and 22Rv1, and AR target gene transcription also decreased in LNCaP. [Prostate] Abstract

Overexpression of AR-Regulated lncRNA TMPO-AS1 Correlates with Tumor Progression and Poor Prognosis in Prostate Cancer

In prostate cancer (PCa) cells, TMPO-AS1 was predominantly localized in the cytoplasm and directly down-regulated by AR. Gain/loss-of-function assays showed TMPO-AS1 overexpression increased cell proliferation by promoting cell cycle progression and promoted migration, but reduced apoptosis of PCa cells. [Prostate] Abstract

Cytotoxicity of AMANTADIG – a Semisynthetic Digitoxigenin Derivative – Alone and in Combination with Docetaxel in Human Hormone-Refractory Prostate Cancer Cells and Its Effect on Na⁺/K⁺-ATPase Inhibition

Scientists evaluated AMANTADIG, a semisynthetic cardenolide derivative, for its cytotoxic activity in two human androgen-insensitive prostate carcinoma cell lines, and the potential synergistic effects with docetaxel. [Biomed Pharmacother] Abstract | Graphical Abstract

In Vitro Cytotoxic and Antiproliferative Effects of Usnic Acid on Hormone-Dependent Breast and Prostate Cancer Cells

Usnic acid (UA) induced apoptotic cell death and G0/G1 cell cycle arrest without damaging normal cells. MCF7 cells were more sensitive to UA than LNCaP cells. [J Biochem Mol Toxicol] Abstract

Long Non-Coding RNA NAP1L6 Promotes Tumor Progression and Predicts Poor Prognosis in Prostate Cancer by Targeting Inhibin-β A

AP1L6 expression was upregulated in prostate cancer (PCa) tissues and cell lines compared with adjacent non-tumor tissues. Researchers found that NAP1L6 promoted the expression of Inhibin-β A (INHBA), and knockdown of NAP1L6 led to the reduction of PCa cell migration, invasion, and proliferation by regulating the expression of INHBA. [Onco Targets Ther] Abstract

miR-93 Promotes the Growth and Invasion of Prostate Cancer by Upregulating Its Target Genes TGFBR2, ITGB8, and LATS2

miR-93 expression was higher in prostate cancer (PC) tissues than in the adjacent normal tissues, and a reduction in the miR-93 level remarkably inhibited the proliferation and invasiveness of PC cells. Moreover, miR-93 enhanced the expression of its target genes TGFBR2, ITGB8, and LATS2. [Mol Ther Oncolytics] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Non-Metastatic Castration Resistant Prostate Cancer: A Review of Current and Emerging Medical Therapies

The authors review and summarize the current literature for the definition, diagnosis and treatment of non-metastatic castration resistant prostate cancer (M0CRPC). They highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

VolitionRx Limited announced preliminary data from a prospective, multi-centered proof of concept study of 84 men into the utility of Volition’s Nu.Q^™ assays to diagnose men with high-grade prostate cancer. [VolitionRx Ltd] Press Release

TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Therapeutic Solutions International, Inc., announced filing of a patent on recent data showing pterostilbene potently augments killing of breast cancer, prostate cancer, and ovarian cancer cells by ozone therapy. [Therapeutic Solutions International, Inc.] Press Release

Top Geneticist Loses £3.5-Million Grant in First Test of Landmark Bullying Policy

One of the world’s largest research-funding charities has revoked a £3.5-million (US$4.5-million) grant awarded to a top cancer geneticist, Nazneen Rahman, following allegations that she bullied scientists and other staff when she worked at the Institute of Cancer Research in London. [Nature News] Editorial

What Pakistan’s New Government Means for Science

Pakistan is reeling from a political earthquake — and researchers are both nervous and excited. On 18 August, the former cricket superstar Imran Khan is expected to be sworn in as prime minister. The incoming administration promises to use science to alleviate poverty, but it is facing an imminent economic crisis. [Nature News] Editorial

The NIH Loosens Grip on Gene Therapy Trials

The directors of the National Institutes of Health (NIH) and the US FDA propose limiting the role of the NIH in assessing proposals for gene therapy experiments, the two explain in a commentary in the New England Journal of Medicine. [The Scientist] Editorial

NEW European Society for Medical Oncology (ESMO) 2019 Congress
September 27-October 1, 2019
Barcelona, Spain

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Translational Cancer Research (University of California, Davis)

Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana)

Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic)

Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Clinical Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

Assistant or Associate Professor – Prostate Cancer (Lerner Research Institute of the Cleveland Clinic)

Postdoctoral Position – Tumor Ecosystem Research (University of Zurich)

Postdoctoral Felllow – Non-Coding RNA & Cancer Research (University of Toronto)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Fellow – Prostate Cancer Metastasis Research (Oregon Health & Science University)

Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.